Patient demographics and baseline characteristics of patients administered anti-PD-1 (n=92)
| Characteristics | PMME (n=28) | NEMM (n=64) |
| Sex | ||
| Female | 11 (39.3) | 48 (75.0) |
| Male | 17 (60.7) | 16 (25.0) |
| Age, years | 60 (42–74) | 57 (27–79) |
| ≤55 | 9 (32.1) | 30 (46.9) |
| >55 | 19 (67.9) | 34 (53.1) |
| Metastases | ||
| M0 | 3 (10.7) | 18 (28.1) |
| M1 | 25 (89.3) | 46 (71.9) |
| Previous systemic therapy | ||
| No | 11 (39.3) | 22 (34.4) |
| Yes | 17 (60.7) | 42 (65.6) |
| LDH | ||
| Normal | 20 (71.4) | 48 (75.0) |
| Elevated | 8 (28.6) | 16 (25.0) |
| ECOG | ||
| 0 | 12 (42.9) | 34 (53.1) |
| 1 | 16 (57.1) | 30 (46.9) |
ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; NEMM, non-esophageal mucosal melanomas; PMME, primary malignant melanoma of the esophagus.